150 related articles for article (PubMed ID: 11679427)
1. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.
Meier JJ; Hücking K; Holst JJ; Deacon CF; Schmiegel WH; Nauck MA
Diabetes; 2001 Nov; 50(11):2497-504. PubMed ID: 11679427
[TBL] [Abstract][Full Text] [Related]
2. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
Meier JJ; Nauck MA; Siepmann N; Greulich M; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
Metabolism; 2003 Dec; 52(12):1579-85. PubMed ID: 14669159
[TBL] [Abstract][Full Text] [Related]
3. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
[TBL] [Abstract][Full Text] [Related]
4. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
Meier JJ; Gallwitz B; Kask B; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetes; 2004 Dec; 53 Suppl 3():S220-4. PubMed ID: 15561915
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.
Thondam SK; Daousi C; Wilding JP; Holst JJ; Ameen GI; Yang C; Whitmore C; Mora S; Cuthbertson DJ
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E224-E233. PubMed ID: 28073779
[TBL] [Abstract][Full Text] [Related]
7. No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.
Nauck MA; Holle H; Kahle M; Tytko A; Deacon CF; Holst JJ; Meier JJ
Peptides; 2020 Mar; 125():170176. PubMed ID: 31669136
[TBL] [Abstract][Full Text] [Related]
8. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Aaboe K; Knop FK; Vilsboll T; Vølund A; Simonsen U; Deacon CF; Madsbad S; Holst JJ; Krarup T
J Clin Endocrinol Metab; 2009 Feb; 94(2):603-8. PubMed ID: 19050053
[TBL] [Abstract][Full Text] [Related]
9. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
10. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
[TBL] [Abstract][Full Text] [Related]
11. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients.
Rudovich NN; Rochlitz HJ; Pfeiffer AF
Diabetes; 2004 Sep; 53(9):2359-65. PubMed ID: 15331546
[TBL] [Abstract][Full Text] [Related]
12. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Hayes TM
Horm Metab Res; 1989 Jan; 21(1):23-6. PubMed ID: 2647605
[TBL] [Abstract][Full Text] [Related]
13. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
[TBL] [Abstract][Full Text] [Related]
14. The effect of age and glycemic level on the response of the beta-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
Meneilly GS; Ryan AS; Minaker KL; Elahi D
J Clin Endocrinol Metab; 1998 Aug; 83(8):2925-32. PubMed ID: 9709971
[TBL] [Abstract][Full Text] [Related]
15. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
16. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
17. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
[TBL] [Abstract][Full Text] [Related]
18. Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.
Eriksen M; Jensen DH; Tribler S; Holst JJ; Madsbad S; Krarup T
Diabetologia; 2015 May; 58(5):920-8. PubMed ID: 25748606
[TBL] [Abstract][Full Text] [Related]
19. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
20. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
